0001104659-21-108597.txt : 20210823 0001104659-21-108597.hdr.sgml : 20210823 20210823164406 ACCESSION NUMBER: 0001104659-21-108597 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20210823 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210823 DATE AS OF CHANGE: 20210823 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cara Therapeutics, Inc. CENTRAL INDEX KEY: 0001346830 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36279 FILM NUMBER: 211197483 BUSINESS ADDRESS: STREET 1: 4 STAMFORD PLAZA STREET 2: 107 ELM STREET 9TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06902 BUSINESS PHONE: 203-406-3700 MAIL ADDRESS: STREET 1: 4 STAMFORD PLAZA STREET 2: 107 ELM STREET 9TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06902 FORMER COMPANY: FORMER CONFORMED NAME: Cara Therapeutics Inc DATE OF NAME CHANGE: 20051213 8-K 1 tm2125639d1_8k.htm FORM 8-K
0001346830 false 0001346830 2021-08-23 2021-08-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 23, 2021

 

CARA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-36279   75-3175693

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

         

4 Stamford Plaza

107 Elm Street, 9th Floor

Stamford, Connecticut

      

06902
 (Address of principal executive offices)       (Zip Code)
         
Registrant's telephone number, including area code: (203) 406-3700
         

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

  

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common stock, par value $0.001 per share CARA The Nasdaq Stock Market LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 8.01 Other Information.

 

On August 23, 2021, Cara Therapeutics, Inc. issued a press release announcing that the US Food and Drug Administration has approved its New Drug Application for KORSUVA™ injection for the treatment of moderate-to-severe pruritus in hemodialysis patients. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d)  Exhibits

 

Exhibit No.  
     
99.1   Press Release dated August 23, 2021
104   Cover page interactive data file (formatted as Inline XBRL)

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CARA THERAPEUTICS, INC.
   
  By: /s/ THOMAS REILLY
    Thomas Reilly
    Chief Financial Officer
    (Principal Financial and Accounting Officer)

 

Date: August 23, 2021

 

 

 EX-99.1 2 tm2125639d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

 

 

Press
Release		 Cara Therapeutics and Vifor Pharma announce U.S. FDA approval of KORSUVA™ (difelikefalin) injection for the treatment of moderate-to-severe pruritus in hemodialysis patients

 

·First and only therapy approved by the FDA for the treatment of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis
·Promotional launch of KORSUVA™ injection in the U.S. is expected in Q1 2022, with reimbursement in H1 2022
·Company to host conference call today at 5.00 p.m. ET

 

Stamford, Conn. and St. Gallen, Switzerland, 23 August 2021 – Cara Therapeutics (Nasdaq: CARA) and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA™ (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis . KORSUVA™ injection is a first-in-class kappa opioid receptor (KOR) agonist that targets the body’s peripheral nervous system. The KORSUVA™ injection new drug application (NDA) received Priority Review by the FDA, which is granted to therapies that, if approved, would offer significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications.

 

“The FDA approval of KORSUVA™ injection is a transformational milestone for Cara and a significant advancement for the substantial number of adult hemodialysis patients suffering from moderate-to-severe pruritus,” said Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics. “We look forward to working closely with our commercial partner, Vifor Pharma, to launch KORSUVA™ injection in the U.S in the coming months. We extend our deepest gratitude to the patients who participated in our KALM-1 and KALM-2 clinical trials, the study investigators, and especially our employees, as their commitment through over 10 years of collective effort made this important milestone possible.”

 

“We are very excited about the FDA approval of KORSUVA™ injection,” said Abbas Hussain, Chief Executive Officer of Vifor Pharma “There is a significant unmet medical need for a targeted therapy, and we believe that KORSUVA™ injection can fundamentally change the treatment paradigm for adult CKD-aP patients undergoing dialysis. We are committed to bringing this first-in-class medicine to U.S. hemodialysis patients as fast as possible, together with our partner Cara Therapeutics.”

 

“We are pleased to see that KORSUVA™ injection has received FDA approval as the first treatment option approved for moderate to severe pruritus in adult CKD patients on hemodialysis”, commented Dr. Frank Maddux, Global Chief Medical Officer of Fresenius Medical Care, “Participating in the robust clinical trial program we have learned that KORSUVA™ injection represents an effective treatment option. We have seen substantial improvement in symptoms and meaningful relief for people suffering from severe and debilitating itch.”

 

This approval is based on the New Drug Application filing that was supported by positive data from two pivotal Phase 3 trials – KALM-1, conducted in the U.S. (New England Journal of Medicine 2020; 382:222-232), and the global KALM-2, as well as supportive data from an additional 32 clinical studies.KORSUVA™ injection was found to be generally well tolerated.

 

1/4 

 

 

Vifor Pharma and Cara have agreed to an exclusive license to commercialize KORSUVA™ in the United States. That agreement features a Cara 60%, Vifor Pharma 40% profit-sharing arrangement in non-Fresenius Medical Care clinics in the U.S. Under a previous agreement, Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics have agreed to market KORSUVA™ injection to Fresenius Medical Care North America dialysis clinics in the U.S. under a Cara 50%, Vifor Pharma 50% profit-sharing arrangement.

 

Vifor Pharma and Cara Therapeutics are in the process of submitting the required documentation to the U.S. Centers for Medicare and Medicaid Services (CMS) to ensure timely reimbursement and patient access to KORSUVA™ injection. Vifor Pharma expects to begin promoting KORSUVA™ Injection in Q1 2022 with reimbursement expected in H1 2022, subject to CMS timelines.

 

Conference Call

 

Cara management will host a conference call today at 5:00 p.m. ET to discuss the approval of KORSUVA injection for the treatment of moderate-to-severe pruritus in hemodialysis patients.

 

To participate in the conference call, please dial (855) 445-2816 (domestic) or (484) 756-4300 (international) and refer to conference ID 1485906. A live webcast of the call can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com.

 

An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.

 

Contacts and further information:

 

Media Contact  Investor Contact
Claire LaCagnina  Janhavi Mohite
6 Degrees  Stern Investor Relations, Inc.
315-765-1462  212-363-1200
clacagnina@6degreespr.com  janhavi.mohite@sternir.com

 

Vifor Pharma contacts:

 

Media Relations

Nathalie Ponnier

Global Head Corporate Communications

+41 79 957 96 73

media@viforpharma.com

  

Investor Relations

Julien Vignot

Head of Investor Relations

+41 58 851 66 90

investors@viforpharma.com

 

About Cara Therapeutics

 

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. In two Phase 3 trials, KORSUVA injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). Oral KORSUVA has completed Phase 2 trials for the treatment of pruritus in patients with CKD and atopic dermatitis and is currently in Phase 2 trials in primary biliary cholangitis and notalgia paresthetica patients with moderate-to-severe pruritus.

 

About Vifor Pharma Group

 

Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).

 

2/4 

 

 

For more information, please visit viforpharma.com

 

About KORSUVA™ Injection

 

KORSUVA is a kappa opioid receptor agonist developed in Cara laboratories and indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD). KORSUVA Injection is not a federally controlled substance.

 

Breakthrough Therapy Designation was received from the FDA for KORSUVA Injection for the treatment of CKD-aP in HD patients and the New Drug Application was evaluated by the FDA with Priority Review.

 

Important Safety Information

 

Warnings and Precautions

 

Dizziness, Somnolence, Mental Status Changes, and Gait Disturbances: These adverse reactions, including falls, have occurred in patients taking KORSUVA and may subside with continued treatment. Concomitant use of centrally acting depressant medications, sedating antihistamines, and opioid analgesics may increase the likelihood of these adverse reactions and should be used with caution during treatment with KORSUVA.

 

Risk of Driving and Operating Machinery: Dizziness, somnolence, and mental status changes have occurred in patients taking KORSUVA. KORSUVA may impair the mental or physical abilities needed to perform potentially hazardous activities such as driving a car and operating machinery. Advise patients not to drive or operate dangerous machinery until the effect of KORSUVA on their ability to do so is known.

 

Adverse Reactions

 

The most common adverse reactions (incidence ≥2% and ≥1% higher than placebo) were diarrhea (9.0%), dizziness (6.8%), nausea (6.6%), gait disturbances, including falls (6.6%), hyperkalemia (4.7%), headache (4.5%), somnolence (4.2%), and mental status changes (3.3%).

 

Use in Specific Populations

 

Severe Hepatic Impairment: The influence of severe hepatic impairment on the pharmacokinetics of KORSUVA in subjects undergoing hemodialysis (HD) has not been evaluated; therefore, use of KORSUVA in this population is not recommended.

Geriatric Use: The incidence of somnolence was higher in KORSUVA-treated subjects aged 65 years and older (7.0%) than in KORSUVA-treated subjects less than 65 years of age (2.8%). The incidence was comparable in both placebo age groups (3.0% and 2.1%, respectively).

 

Indication

 

KORSUVA is indicated for the treatment of moderate to severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD).

 

Limitation of Use: KORSUVA has not been studied in patients on peritoneal dialysis and is not recommended for use in this population.

 

Please see KORSUVA™ injection full Prescribing Information at www.korsuva.com.

 

About Chronic Kidney Disease-associated Pruritus

 

CKD-aP is an intractable systemic itch condition that occurs with high frequency and intensity in patients with chronic kidney disease undergoing dialysis. Pruritus has also been reported in patients with stage III-V CKD who are not on dialysis. Aggregate, longitudinal, multi-country studies estimate the weighted prevalence of CKD-aP to be approximately 40% in patients with end-stage renal disease (ESRD), with approximately 25% of patients reporting severe pruritus. The majority of dialysis patients (approximately 60 to 70%) report pruritus, with 30 to 40% reporting moderate or severe pruritus.1,2,3 Recent data from the ITCH National Registry Study showed that among those with pruritus, approximately 59% experienced symptoms daily or nearly daily for more than a year. Given its association with CKD/ESRD, most afflicted patients will continue to have symptoms for months or years, with currently employed antipruritic treatments, such as antihistamines and corticosteroids, unable to provide consistent, adequate relief. Moderate-to-severe chronic pruritus has repeatedly been shown to directly decrease quality of life, contribute to symptoms that impair quality of life (such as poor sleep quality), and is associated with depression.4 CKD-aP is also an independent predictor of mortality among hemodialysis patients, mainly related to increased risk of inflammation and infections.

 

3/4 

 

 

Forward-looking Statements

 

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements include statements concerning the potential timeline for launch of KORSUVA™ injection, the potential timeline for reimbursement and the potential of KORSUVA™ injection to be a therapeutic option for CKD-aP in dialysis dependent patients. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Cara's filings with the Securities and Exchange Commission, including the "Risk Factors" section of Cara's Annual Report on Form 10-K for the year ended 31 December 2020 and its other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Cara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

 

References:

 

1 Pisoni RL, et al. Pruritus in haemodialysis patients: international results from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant. 2006; 21:3495-3505.

2 Ramakrishnan K, et al. Clinical characteristics and outcomes of end-stage renal disease patients with self-reported pruritus symptoms. International Journal of Nephrology and Renovascular Disease. 2014; 7: 1-12.

3 Sukul et al. Self-reported Pruritus and Clinical, Dialysis-Related, and Patient-Reported Outcomes in Hemodialysis Patients. Kidney Med. 2020 Nov 21;3(1):42-53.

4 Mathur VS, et al. A longitudinal study of Uremic Pruritus in hemodialysis patients. Clin J Am Soc Nephrol. 2010; 5(8):1410-1419.

 

 

4/4 

 EX-101.SCH 3 cara-20210823.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 cara-20210823_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 cara-20210823_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2125639d1_ex99-1img001.jpg GRAPHIC begin 644 tm2125639d1_ex99-1img001.jpg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

;9.P/FJO>2)PLBX^8A60'#L#_3!;7T.OZ(ES8W M2207D DM[F!UD5E9L??EIW6_3IY-% M<'?V=F.#4:E&'M(Z2]U:]GMUZ^9\DC_@@=^RAA M8[N%@'BG3+YVO&RL!VS@\@U^A7_!);XO_&']HG]G(_$#XLW&GC_A)IO,T"SM MM-^R-'9IE?M#\Y/G,25!&-B(X)$G'PL.*,PE/D6(J7_Q2_S/UK-O#&EE^!AF M%>G1=.5N6R3;OJK>ZNFI@W7_ 0=_9+L+5II?A?Y<4:EF=_$^K@(!R22;K@" MOP9_;1UWX:ZY^TIXH;X1:!_PCOP]M+@6FCV[7=Q=/Z"LBW&O7:IC[GX!QI]5EB89; M@*45*ZORI)W>RNE\V?HU_P &V/\ P3__ .$A\0WGQ^\26W^B:3)+I?A2)Q_K M;@J4NKO!'1%;RD()RS39 **3^S6:Y7X)?!_0?V?_ (3>'_!?AFS6PT'PU8QV M%G"HYV(,;W( W2,AY'B'M'H7B'XVZ'H'P,N_B(;A9_#=MH;:^LZ'(F MMA!YZE<9R67&,9SD8S7P3_P1 ^&6I_%_XI_$KX^>*%CGU+6;V;3[24* K7$S MBYO'5#]P*&@1"#C#R+VKY[U3]NR3Q-_P2CT/X/VUS-<>+KCQ =':UBC9YIM* MC9;J,YY.3-)%"BK@LL+#L=WZO?L=? *#]F#]FGPCX)B"^?H]@IOG5MXFNY"9 M;AP>I4RN^WT7:.U 'PK_ ,%,?^4S'[/W_8_P#!3'_E,Q^S]_W+G_I\N:]._P"#@K_DS/PS_P!CI:_^D-_0!V?[ M*/PA_9[U/]EKX:W.M>%_@U<:Q<>%=+EOY;[3=->YDN&M(C(TI==QD+EBQ;G. M<\U[;\./#/PL^$_A_7-<\#Z+X'TFUM[)O#]AJUU%;7]FL,1%% XX(9BB;B=S9_3#Q+^R#\*_&7@[_A']0^'7@R31PNV.UCTB"$0 M<$9C**IC8!CAD((R<'FOS\_X(1_%>/X/?&3XA_";Q3)_9&N:A-&]G97.R,B\ MM&EBNH,]6EP4(7)X@?]AJX_P#1 KR+]JOQ M/IO[>?\ P6'\#Z+X2N%U32?#\MAI-S?VCYCFBM9Y;R[EC?# A!)*@;&TM&,9 M4ACZ[_P_A;^S7)^QOX#O_%F@_!N*YD\'Z;- MJUY>6NGQ77FFSB,KR2X$@D+$Y.=VXGO7SI_P14^RV_[?WQ=M_!GVX_#L6%]] MB)+M"(AJ,0L=['.9/(,NW<8><&O,?VF_^"7>G_#7]@KP'\8/!]WXBU2[U M+2-/U3Q)9W;Q2Q6L=U;1R&6$)&K+&DK;2&+G:X.?E)/Z$?\ !*G5/AKXI_9. MTG5_AWX>TGPY-<*MKX@MK0,TR:A$HWK+(Y:1Q\^]-[-A)1TR10!],4444 %% M%% !1110!^=?_!P1XEO++P-\--'CDD_LZ^OK^\G0?=:6&.!(R?H)Y?S-?)/_ M 2K\!:3\1OV[/ ]CK$,=U:VTEQ?I"_W9)H())HLCOM=%;'?;SQ7Z:?\%1/V M1;[]KG]G-K/0DB?Q/XOE:?LQ?M2>$_VK_AO;>(O"]_'-\JB]LF< M?:M-E(YBE3J#G.#T8#()%>E@\5]-"<9Q4HNZ9]%&2DKQ(+NWCO(&CD19(Y%* MLK#*L#P016/X#^'FB_#716L-#T^UTVS:1I3' FT,YZL?4_7L .@%87Q9^,-I MX'L)K6WD6;5G7"1KSY.1PS?S ZGCMS6#^SE\0[[Q!+>:9?S274D8\^*61MS M$@,I/U((^I]J_.L1XG9'#B6EPU&7/7FG=QLU%I746^C:3T\M3NC1K>P;3:B[ M-KO;K;RN>LGJ*_"+_@I3J]QK7[=/Q*ENF+2)JQ@7=V2.-(T'_?"K7[NDXK\= M?^"UGP&O?AK^UI/XL6$_V-XZ@CN895'RI<0QI#-&??Y4D]_-]C7U^=Q;H)KH MSYW.(MT4UT9^J'[,WAFQ\&_L\>!]+TU$2QL]"LDBV#AAY*$M[EB22>Y)-=T# MUK\^_P#@F7_P5/\ !\GPIT?X?_$+4K?PSJWARU2QL=3O9MMG?VZ#;&'D/$3H M@"_.=K!00V3M'V5XF_:5^'W@SPXNK:IXV\)V6FRIOBN)-5@V3#K\GS?/[!QK3K0J7Y'>Q\E?\%F/VA&^#?[)5SHEC<^1JWCR?^RD"G$@M0-]RP]MN MV,_]=J^1?^"*GP)L]7^+VI?%#Q%<65AX?\%H;6TGO)5CBDOYU*C#,0OR1%CZ M[I(R*\[_ ."K?[4#?M(_M5ZG!:R;M!\&%]%TX*Q*S,CGSY_3+R9 (ZI&E>Y> M._\ @GG\7/%?[&'PL\">#=+L3IS0R>)O$337T5LUSJ%SS%&RL18U.U3DC+\3/^QR MU3_TNEKLSSX8>IU9Q\,?4_1C]M7_ (*\ZO\ LH_M#ZOX(M?!.GZQ#I<-M*MW M+J+PM)YL*2D%0A QNQU[5\I?M=_\%=_%W[5?PFOO!?\ PC>C^'='U1XFO7AF MDN+B98W615#':%7>JD_+DXQG!.?TB^.__!.?X2?M%^+M0\1>)O#+W7B+5(%A MDU"/4;J)DV1B.-@BR"/*J%ZK@XY!YK\ULKS4/".I1 M7,0N8!+::C$K+)$Y1LAHY$VDJ?4@\@USYC+%4_BE[DF]NW;8Y\P^LTW[TO<9 M]G_\$&_V>M6M/%OB;XDW]E<6NE2:?_8VF2RJ56]9Y4DF=,]0GE(N[IER!R#C M]-5.17F?[)_[2GAO]JCX+Z;XI\,[K>U;_1;FR90'TZX15WP,!Q\H92"."K*> M^*]$U#48=(TZ:ZN)4AM[:-I99&.%C11DDGT !KVL'1A2HI1=UO<]C!TX4Z*4 M7==SX%_X+R?M!'PU\,_#?PYL;E5N?$DYU34XU/S?983B)6_V7FRP][>N*_X( MN? #0= \$>*/B1XVGTJST_Q)#)X:TI-0F6%+F#K=$;R 0S!4&.?DD'>OE#]M M/XZ3?MD?M<:UKVDI<75KJEW%IFB6[C#F!,10@*?NF1LN1V:4U]7_ +7G_!-; MXQ?$/2O ?@WPEIFFS^#/A[H,%E S:C# +V^D DN[K83D%Y#CG^YD?>.?#]I* MKB)XB,>91T2_KYL\7VDJN(E7C'F4=$OZ^;/CSXW^&)/V2?VL]5MO"NK+<+X5 MU9+S1+^&=9M\0*S0,70[6.TJ&QW## Z5^Z'P2^*-C\;/A+X<\6::RM9^(+"& M]0 Y\LNH+(?=6RI]U-?B-^T?_P $_/B=^RGX*M?$'C#2K.UTNZO%L4FMKZ.X MVRLCNH8*20"$;GIQ[U]I_P#!"?\ :?\ [=\)ZQ\*=09OM.B>9K&E.7SNMW=1 M-$!VVR.''KYSQP3@]C@UT.>::RYHC)QDI1T:)G!3BXRV9_* MS^W!^R5KG[$/[3'B;X>ZT)IAI<_F:=>O%L74[%\M!<*.1\R<, 2%=73)*FOU MP_X-ROV_X_C%\%9O@OX@N_\ BIO -OY^BO*Q+:AI1?&P?[5N[*F,_P"KDBP# MM8CK?^#@O]@)?VFOV:/^%B>'[*-O&GPSADNI2N?,O]* 9YX0!U:,XF7/0+(! MR]?B1^RK^TAX@_9&_: \,_$+PS)MU/PY>+.86;$=] ?EFMGX/R2QET) R-V1 MA@"/WBG*GQ3D'*_XT/\ TI+?TDOS?8_%9J?#F=\R_A2_&+_5,_?K_@I/_P $ MH=%_;R^)OP[\2>;#I=[H6HQVOB&4?(VIZ/DR/$& W>QCOK8N1OC##YHW ) =&#(PR<,K#M7YF_\ !T+\ M>_%GAOP)X"^'=C8W%IX/\3R3:GJ.HAOEOY[9E$=IP> F\2L&'S$Q$?ZMJ_'\ MDR5XS,HX&7NN3][NK;_/1_,_8N(.*:]/*(U)2YX4T^1=/>>GX_@?EC^V7^U' MKG[9?[27BCXA:\\@FUR[)M+9FRNGVB?+!;KVPD84$C[S;F/+$U^R'_!NU^P& MOP"_9];XM^(K)8_%GQ(ME.F[L[[+1B5>(>@-PRK,<9R@@Z$$5^8G_!(S]@NZ M_;U_:STO2;RW<^"?#+QZKXFN,<&W5LI;#D?-.ZB/@Y">8X!V8/\ 2O;6L=C; M+#'&D<<:A$1%VJJC@ = *_2O$3.H87#PR3":))[^7<_,>!*?$4/A'PSJ&JW"2O;Z;:RW4JQ %V2-2Y"@D#. < M9(KXH_XB"O@U_P!"S\3O_!=8_P#R97XZ?K!]U45\W_LM_P#!4WX2?M9^*(-! MT/4M2T?Q'=(SV^EZS:"WFN=N=P1T9XF;:-VT/NVG./E;&S^VE_P4%\&_L*?\ M(W_PEVF>)]1_X2G[5]D_L>V@F\O[/Y._S/-FCQGSTQC/1LXXR >#_#__ ((Q M6O@7]NR/XF+K^GR^$;/7)=>LM#6T:.:"8[I88PP.T)%.59>N5B4$(8?%WAG3]5MTE2WU.UBNHEE #JDBAP& )&<$9P37C7QQ_X*!^#?V?_ -IC MP?\ "K6=,\37/B+QM]B^PW%E;0/91?:KI[6/S6>97&'C);:C84C&3Q0!PO[5 MG_!/'6/VA/VYOAO\6+/Q%INGZ?X'_LOS[":!VFNOLFH2W;;6'RCE:U8Z'<:?KL.KM/=Q/(CHEO<1% %YR3,#_P$U]#5 MXI^V5^W9X+_8:\.Z+J'BZ'6KQO$%S);V=II444MPXC4-)(5DDC&Q=R D$G,B M\<\ '>? 7X=S?"+X&^#/"=S<17ESX7T*QTB6>)"J3O;VZ1%U!Y )0D9]:Z^N M7^#GQ8T?X[?"S0?&&@323:3XALTO+8R "2,,.4< D!T;*L 3AE(R<5#\<_C# MIO[/_P )->\9ZQ#?7.E^';4W=S%9(CW#H"!A [*I//=A]: /G#]O;_@D[X?_ M &N?%,7C#P_JO_"$^.H@OG7L5OO@U(KC8TJJ5995Q@2J--G\/R'9< :]J,LTT>""'S;JTH.>5>3!X]!7H'_ !$%?!K_ M *%GXG?^"ZQ_^3*]O_95_P""D/PK_; U-M-\+ZQE1Q:5#%+,)7BFE! M(DDC7;MA;G=G)''4CG_V,/\ @HGX#_;FO=>M?"=KXBTV[\/I%+/!K%M#"\L< MA8!X_*ED! *X.2"-R\%OV9_#WPZUY;?6K/3_ Q;>'-1&TB& M_C2U6WEXZ[7 ;CK@U\Z_L _\$X?&7["7QE\07=GXTTW6O OB!7CETV2W=+KY M&8VTV[[OFJ"5;&%(D;CADD_O[%1]GM4BI+LSXN^%?[/7P4^!?B>/7O"?A'Q M-INL1#Y'C\27L*^NUMDWS+ZJP(/<5ZGXE_:2US6%9+-8=-C(QE?WCC_@1X_( M5Z!XA_9RT#6[MIH?M&GLQW%8&&PG_=(./H,5EP_LJ::&_>:E?,OHH0'\\&OY MKX@X:\8,0W@Z6(C[-_:IN,+^>RDOD>EA_J-->[&WR/%F-QK.H?\ +:ZNKA_= MY)6/ZDU[W\ OAG-X+TF:\OH]FH7V!LSDQ(.@/N3R?PK>\%?"C1_ O[RSM]UP M1AII6W.P_D/P KIL8/\ .OJ/"7P*EP_C%G>=555Q.MDM5%O=MM)MV^ZY.*QW MM(^S@K(&&17#_'S]GKPK^TM\/[CPWXNTJ'4M/FR8F("SVDF"!+"_5'&>HZC( M(()![AL 48R*_I*45)3P%-9>--$=LP)) M5^?[J]*\UT?_@DE^T!K%Z(?^$#>T7=AI;G5;)43W_UQ M)'^Z#7[?9P:!S7DRR6@Y75T>9+)Z#=U='P)^QU_P1'T/X=7MKKWQ2O+7Q3J< M.)$T6V!_LV%NWFLP#3]OEPJ=00XK[-^+\'B"R^#FO6_@FUMCXD7398-(B=UA MABG*;8SD\!4)!Q_LXKK@>#1G"UWT<+3I0Y(*WYG;1P\*<.2"L?E#^S+_ ,$; M/B-9?M!>&]0^(FEZ3)X3M;W[9J:KJ,=PUR$5G6,H.6#R!%;_ &6:OU<10B[< M8"C IV#F@**6%P=.@FH=0P^%A134.IS_ ,3_ (=:7\7?A]K'AG6[?[5I.N6D MEG=1@[6*.,$J>S#J#V(![5^5/@C_ ()+?'[X,?&'3_$7AJRT.:3PYJBWFGSO MJL2>>LM^([[4K5WU2-&:& M6YDD0E3R#M8<5^M7WA2=Z,1A*==)5+Z%8C"PK)*?0 . *^4?^"H?[ ?_ U[ M\/[75/#-G8K\0-%D1+::1EA^W6Q;#P2.>R[BZD]"& ^^:^K\[1TI#][K6U:C M"I!TY;,TK48U(.$MF?GS_P $S/V0_CQ^QM\69H=:TO39O _B)?+U.&'5(I&M M95!\JX1,C)!^5@.JL>"545]4?MO^#O&WQ"_9F\3>'/A_#;R>(/$$(T\--*?B/I>DC2?#\#WEC'%>)<[[X%1"2H[)EW! M[,B5^ERC]*;!,LT0965D89!4Y!_&G@C%/#86%"/+ >'P\*,>6!YK^UK^SY8? MM/\ P!\1>#KY!OU&W+V4N=IM[I/FAD!]G SZJ6'>OSY_8V_X)K?'K]FG]I/P MKXO&EZ,MEI]XL6HHFK1L9+.3]W.-N>3L9B!_>5?2OU/V\4XC-16P=.I.-5W3 M78FM@Z=2:J2W0#I11178=04444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110!'-$LR,K %6&"",@BOYN/\ @L[^P5_PPM^UU?0Z/936_@/Q MIYFK^'FV8AMP6'GV:D #]P[ !>2(I(-K6^M)+[0_$'AV^ M2X@E&Z"ZT^Z@D#*PZ,DB.H/J"OM7].7_ 3=_;/TW]O#]DWP[XZM?+AU;:=. MUZT7'^A:C$JB9, G"L&25.<^7+'G!R!]5Q]E,\#C*>W7QUXB(U+Q-/$ M^\>><^7 &Y&V&,A."5+^8PX>OJG.&HQ0!S7YCC,95Q=>6(KN\I.[_KMT7D?H MN#PE/#48T**M&*LCFOC9_P D9\7?]@6\_P#1#U^:7_!$?QY\*?"'PM\<1_$+ M6?A[I=Y-JL#6B^(KNS@E>,0D$QB<@E<]<<9K]+?C9_R1GQ=_V!;S_P!$/7Y3 M?\$BO^"?OPZ_;(^'/B_4_&MKJT]UHVI0VML;2^:W4(T6XY ')S7.=)'^V1KG MP_\ BE_P4K^&J? 6UL;C5K?4;+[?/X>MDCL[F]6[\WS8V0!'*IEI)1\F%R6. MUB/3/^#C/_FCG_<;_P#U3Z5\5?\'&?_-'/^XW_ .X^@#ZB^$__ 4@^!NB_"WPW9W7 MQ,\-PW5II5K#-&TC[HW6% RGY>H(-?&/[9_QS\(_M _\%'K*6YM&)1)EUF9RAR!R%D0_\ A7U1\+?^"17[//B+X:>'=0O/A[YUY?: M9;7$\G]NZFN]WB5F.!< #))X Q7R/^U?^S5X)_9:_P""L?P)\/\ @/1?["TF M\O?#^HS6_P!LGNM\[:S+&S[IG=AE8D& \(L;1W$>$RS'!!YH ^AO\ @A5\==0T2U\: M_ _Q0OV'6O!][+>V-K,<31#S#%>6Y'3]U,%;N29W[**^G/\ @II_R85\4/\ ML"O_ .AI7Y20EBC[R"YVR.K ;0/T^_X*.:I;Z[_ ,$]?B/?6:!Y\$B$/V,K6#QUKWPQT_7(]4O9)(-;O+)+WR]P*G9*?,(( MSCCGM7C&JWO@OXF?\%D?A]#GBO4/^""OQ,\(_P#"->)O!-QH.FZ)\2-'D:2>[:V6*]U: MR+\HQ/SEH)/E9< /$>3NP =A_P<%?\ )F?AG_L=+7_TAOZ^7OV7!)^P1^W3 M\%]8P(/"WQ<\&Z-YTLC;$ O[6!9MSX"C9?1K*1V0KDC.ZOJ'_@X*_P"3,_#/ M_8Z6O_I#?UYQ_P % ?V>?^%F?\$D/@SXTLK?S-4\ ^&-%FF95RS6,]E;Q2C@ M9.V3R'ZX55D)]0 >G_\ !=?X]R?#[]F+3?!.FW$RZM\0-06"2*'[[V4&'E'' MS?-*8%P!\P+@G&0?EK]C+X$_\,T_\%G?!?@EO^/K1=/'VSYMP^U2^&FFN,') MX\Z23&#C&,<5N_LR^.]4_P""I?\ P40^'>O:Q97?]C_#+P]97>HAV_=275L M[28S@>;?2#"DLS11C=P"%[+_ )V0?\_]"O0!^F&HZA#I&GSW5S*D-M;QM++( MYPL:*,LQ/8 FOQSTSX-ZI_P5=^)7[0WQ07[?Y&@:86\,0MP7F0AK:W'1>;: MWD5E[/:3?7+ZJUWJ&G7$EQ=R2J@WL4ND7[ MB1J,*.%&>H **** "BBB@ HHHH **** "O/_ -H?X >$ MOVA_ G]E^,=)_MC3]/D-_;Q?:IK?9,L;J'S$ZD\.PP3CGI7H%1W-NMW;R1OR MLBE&^A�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end XML 7 tm2125639d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001346830 2021-08-23 2021-08-23 iso4217:USD shares iso4217:USD shares 0001346830 false 8-K 2021-08-23 CARA THERAPEUTICS, INC. DE 001-36279 75-3175693 4 Stamford Plaza 107 Elm Street 9th Floor Stamford CT 06902 203 406-3700 false false false false Common stock, par value $0.001 per share CARA NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover
Aug. 23, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 23, 2021
Entity File Number 001-36279
Entity Registrant Name CARA THERAPEUTICS, INC.
Entity Central Index Key 0001346830
Entity Tax Identification Number 75-3175693
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 4 Stamford Plaza
Entity Address, Address Line Two 107 Elm Street
Entity Address, Address Line Three 9th Floor
Entity Address, City or Town Stamford
Entity Address, State or Province CT
Entity Address, Postal Zip Code 06902
City Area Code 203
Local Phone Number 406-3700
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.001 per share
Trading Symbol CARA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://caratherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2125639d1_8k.htm cara-20210823.xsd cara-20210823_lab.xml cara-20210823_pre.xml tm2125639d1_ex99-1.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2125639d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tm2125639d1_8k.htm" ] }, "labelLink": { "local": [ "cara-20210823_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "cara-20210823_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "cara-20210823.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "CARA", "nsuri": "http://caratherapeutics.com/20210823", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2125639d1_8k.htm", "contextRef": "From2021-08-23to2021-08-23", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://caratherapeutics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2125639d1_8k.htm", "contextRef": "From2021-08-23to2021-08-23", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001104659-21-108597-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-108597-xbrl.zip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end